{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:40:04Z","timestamp":1793367604590,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.bmcl.2022.128928","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T12:42:31Z","timestamp":1660135351000},"page":"128928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)"],"prefix":"10.1016","volume":"74","author":[{"given":"Timothy M.","family":"Caldwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Mi","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie L.","family":"Bulfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia B.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly M.","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ping","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshminarayana","family":"Vogeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subha","family":"Vogeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Le Bourdonnec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128928_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.00001","article-title":"Function of CSF1 and IL34 in macrophage homeostasis, inflammation, and cancer","volume":"10","author":"Lin","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2022.128928_b0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nri2356","article-title":"Colony-stimulating factors in inflammation and autoimmunity","volume":"8","author":"Hamilton","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmcl.2022.128928_b0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coi.2005.11.006","article-title":"Colony-stimulating factor-1 in immunity and inflammation","volume":"18","author":"Chitu","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.bmcl.2022.128928_b0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nri2528","article-title":"Trophic macrophages in development and disease","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bmcl.2022.128928_b0025","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1078-0432.CCR-19-1486","article-title":"Colony-stimulating factor 1 receptor (CSF1R) activates AKT\/mTOR signaling and promotes T-cell lymphoma viability","volume":"26","author":"Murga-Zamalloa","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2022.128928_b0030","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmcl.2022.128928_b0035","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/brain\/awv379","article-title":"Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer's-like pathology","volume":"139","author":"Olmos-Alonso","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.bmcl.2022.128928_b0040","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1093\/brain\/awz241","article-title":"CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice","volume":"142","author":"Mancuso","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.bmcl.2022.128928_b0045","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1096\/fj.201900567RR","article-title":"Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration","volume":"34","author":"Neal","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.bmcl.2022.128928_b0050","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s12276-020-0484-z","article-title":"The M-CSF receptor in osteoclasts and beyond","volume":"52","author":"Mun","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.bmcl.2022.128928_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms19061709","article-title":"Cellular and molecular mediators of bone metastatic lesions","volume":"19","author":"Battafarano","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2022.128928_b0060","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1073\/pnas.0507321103","article-title":"A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells","volume":"103","author":"West","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmcl.2022.128928_b0065","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-019-01210-0","article-title":"Pexidartinib: first approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bmcl.2022.128928_b0070","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/DDDT.S253232","article-title":"Pexidartinib, a novel small molecule CSF-1R inhibitor in use for tenosynovial giant cell tumor: a systematic review of pre-clinical and clinical development","volume":"14","author":"Benner","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmcl.2022.128928_b0075","unstructured":"Pexidartinib was purchased from MedKoo Biochemical (Lot #BBC50426) and assayed in our internal enzymatic biochemical assays."},{"key":"10.1016\/j.bmcl.2022.128928_b0080","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmcl.2022.128928_b0085","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1158\/1535-7163.MCT-21-0361","article-title":"Vimseltinib: a precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages","volume":"20","author":"Smith","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2022.128928_b0090","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1182\/blood.V81.10.2511.2511","article-title":"Expression of human colony-stimulating factor-1 (CSF-1) receptor in murine pluripotent hematopoietic NFS-60 Cells induces long-term proliferation in response to CSF-1 without loss of erythroid differentiation potential","volume":"81","author":"Bourette","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2022.128928_b0095","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1158\/1535-7163.MCT-09-0255","article-title":"JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor\/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia","volume":"8","author":"Manthey","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmcl.2022.128928_b0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tibs.2010.09.006","article-title":"Protein kinases: evolution of dynamic regulatory proteins","volume":"36","author":"Taylor","year":"2011","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.bmcl.2022.128928_b0105","doi-asserted-by":"crossref","first-page":"E4623","DOI":"10.1073\/pnas.1418402111","article-title":"Dynamic architecture of a protein kinase","volume":"111","author":"McClendon","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bmcl.2022.128928_b0110","unstructured":"Molecular Operating Environment (MOE), 2019.01; Chemical Computing Group ULC; 2019."},{"key":"10.1016\/j.bmcl.2022.128928_b0115","unstructured":"Ahn Y, Vogeti, L, Caldwell, TM, Kaufman, MD, Flynn DL. Preparation of pyrimidine derivatives as anti-cancer and anti-proliferative agents. WO2014145025, 2014."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22004048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22004048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:45:33Z","timestamp":1760773533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22004048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":23,"alternative-id":["S0960894X22004048"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128928","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128928"}}